Clinical Pharmacokinetics and Pharmacodynamics of Cholinesterase Inhibitors

被引：0
|
作者：
Michael W. Jann
Kara L. Shirley
Gary W. Small
机构：
[1] Mercer University,Department of Clinical and Administrative Sciences, Southern School of Pharmacy
[2] Albany College of Pharmacy,Department of Pharmacy Practice
[3] University of California,Department of Psychiatry and Biobehavioral Sciences, Center on Aging and Alzheimer’s Disease Research Center
[4] Mercer University,Southern School of Pharmacy
来源：
Clinical Pharmacokinetics | 2002年 / 41卷
关键词：
Cholinesterase; Fluvoxamine; Cholinesterase Inhibitor; Rivastigmine; Tacrine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Cholinesterase inhibitors are the ‘first-line’ agents in the treatment of Alzheimer’s disease. This article presents the latest information on their pharmacokinetic properties and pharmacodynamic activity.
引用
收藏
页码：719 / 739
页数：20
相关论文
共 50 条
  • [1] Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors
    Jann, MW
    Shirley, KL
    Small, GW
    CLINICAL PHARMACOKINETICS, 2002, 41 (10) : 719 - 739
  • [2] CLINICAL PHARMACOKINETICS OF CHOLINESTERASE-INHIBITORS
    AQUILONIUS, SM
    HARTVIG, P
    CLINICAL PHARMACOKINETICS, 1986, 11 (03) : 236 - 249
  • [3] Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors
    Maddalena Centanni
    Dirk Jan A. R. Moes
    Iñaki F. Trocóniz
    Joseph Ciccolini
    J. G. Coen van Hasselt
    Clinical Pharmacokinetics, 2019, 58 : 835 - 857
  • [4] Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors
    Centanni, Maddalena
    Moes, Dirk Jan A. R.
    Troconiz, Inaki F.
    Ciccolini, Joseph
    van Hasselt, J. G. Coen
    CLINICAL PHARMACOKINETICS, 2019, 58 (07) : 835 - 857
  • [5] Cholinesterase Inhibitors: Applying Pharmacokinetics to Clinical Decision Making
    Gomolin, Irving H.
    Smith, Candace
    Jeitner, Thomas M.
    AMERICAN JOURNAL OF GERIATRIC PHARMACOTHERAPY, 2011, 9 (04): : 259 - 263
  • [6] Pharmacodynamics, pharmacokinetics and clinical efficacy of phosphodiesterase-5 inhibitors
    Hong, Jeong Hee
    Kwon, Young Suk
    Kim, Isaac Yi
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2017, 13 (02) : 183 - 192
  • [7] Pharmacokinetics and Pharmacodynamics of β-Lactamase Inhibitors
    Crass, Ryan L.
    Pai, Manjunath P.
    PHARMACOTHERAPY, 2019, 39 (02): : 182 - 195
  • [8] Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology
    Bruin, Maaike A. C.
    Sonke, Gabe S.
    Beijnen, Jos H.
    Huitema, Alwin D. R.
    CLINICAL PHARMACOKINETICS, 2022, 61 (12) : 1649 - 1675
  • [9] Pharmacokinetics and Pharmacodynamics of Promising Arginase Inhibitors
    Khaled S. Abdelkawy
    Kelsey Lack
    Fawzy Elbarbry
    European Journal of Drug Metabolism and Pharmacokinetics, 2017, 42 : 355 - 370
  • [10] Pharmacokinetics and Pharmacodynamics of the Proton Pump Inhibitors
    Shin, Jai Moo
    Kim, Nayoung
    JOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY, 2013, 19 (01) : 25 - 35
12345